Defining a correlate of protection for chikungunya virus vaccines

Gregg N. Milligan, Barbara S. Schnierle, Alexander J. McAuley, David W.C. Beasley

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.

Original languageEnglish (US)
Pages (from-to)7427-7436
Number of pages10
Issue number50
StatePublished - Nov 28 2019


  • Animal models
  • Arbovirus
  • Assays
  • Clinical trial
  • Neutralizing antibodies
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Defining a correlate of protection for chikungunya virus vaccines'. Together they form a unique fingerprint.

Cite this